posted on 2014-04-23, 00:00authored byMin Zhu, Yufang Zhu, Bin Ni, Ning Xie, Xuhua Lu, Jianlin Shi, Yi Zeng, Xiang Guo
In an attempt to improve implant-bone
integration and accelerate
bone fracture healing from resisting osteoclastic resorption point
of view, we have employed a novel procedure to develop a mesoporous
silica nanoparticles/hydroxyapatite (MSNs/HA) composite coating onto
stainless Kirschner wire substrate. Characterizations of the surface
microstructures indicated enlarged specific surface area compared
to HA-coated wires as control, thus the MSNs/HA composite coated implants
are endowed with abilities to locally deliver biomedical substances
and enhance fracture healing. Herein, zoledronic acid (ZOL) as a model
drug, different doses of which were immobilized in the mesoporous
coating toward decreasing osteoclastic resorption activity. The loading
capacities of ZOL increased almost eight-folds to that of pure HA
coating, and the introduction of MSNs obviously retarded ZOL release
to achieve a more sustained release profile. After certain periods
of osteoclast like cells co-culturing with ZOL contained wires, tartrat-resistant
acid phosphatases (TRAP) staining of polynucleated cells and a pit
formation assay were performed to investigate the ZOL dose-dependent
anti-resorption activity. The promoted local effect on osteoclasts
will be of clinical benefit to support implant integration and bone
repair.